{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:55:31Z","timestamp":1768784131416,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100067","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:01:22Z","timestamp":1737212482000},"page":"100067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed\/refractory myeloma: survival and correlative analysis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-734X","authenticated-orcid":false,"given":"Aaron S.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-6294","authenticated-orcid":false,"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-9841","authenticated-orcid":false,"given":"Elizabeth A.","family":"Brem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew Joseph","family":"Wieduwilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-0583","authenticated-orcid":false,"given":"Guillaume","family":"Luxardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kaesberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3555-8429","authenticated-orcid":false,"given":"Samantha","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bneo.2025.100067_bib1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2025.100067_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.bneo.2025.100067_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100067_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100067_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2025.100067_bib6","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100067_bib7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10192","key":"10.1016\/j.bneo.2025.100067_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bneo.2025.100067_bib9","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100067_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bneo.2025.100067_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.bneo.2025.100067_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.bneo.2025.100067_bib13","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.bneo.2025.100067_bib14","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100067_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.bneo.2025.100067_bib16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ajh.26361","article-title":"A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)","volume":"96","author":"Voorhees","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100067_bib17","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41375-018-0038-8","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"32","author":"Krishnan","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2025.100067_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000438855","article-title":"Clarithromycin synergistically enhances thalidomide cytotoxicity in myeloma cells","volume":"135","author":"Qiu","year":"2016","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100067_bib19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0091-6749(99)70175-2","article-title":"Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy","volume":"103","author":"Fost","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100067_bib20","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood-2012-08-448563","article-title":"BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100067_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/bloodadvances.2018028027","article-title":"Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma","volume":"3","author":"Mark","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bneo.2025.100067_bib23","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100067_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2025.100067_bib25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100067_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bneo.2025.100067_bib27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bneo.2025.100067_bib28","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2025.100067_bib29","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.bneo.2025.100067_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100067_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-021-00490-8","article-title":"Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial","volume":"11","author":"Puig","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.bneo.2025.100067_bib32","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK cells: an update","volume":"196","author":"Michel","year":"2016","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.bneo.2025.100067_bib33","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-19-0438","article-title":"A phase I study of the combination of rituximab and ipilimumab in patients with relapsed\/refractory B-cell lymphoma","volume":"25","author":"Tuscano","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.bneo.2025.100067_bib34","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-20-4622","article-title":"Long-term follow-up and correlative analysis of two phase II trials of rituximab and lenalidomide followed by continuous lenalidomide in untreated and relapsed\/refractory indolent lymphoma","volume":"27","author":"Tuscano","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bneo.2025.100067_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101435","article-title":"Memory CD8+ T cell responses to cancer","volume":"49","author":"Han","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.bneo.2025.100067_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"Huo","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100067_bib37","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/biomedicines10112826","article-title":"The role of TIM-3 and LAG-3 in the microenvironment and immunotherapy of ovarian cancer","volume":"10","author":"Koz\u0142owski","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.bneo.2025.100067_bib38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11912-022-01218-y","article-title":"New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors","volume":"24","author":"Gomes de Morais","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bneo.2025.100067_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1014904","article-title":"Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:09:47Z","timestamp":1756127387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000020"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100067","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed\/refractory myeloma: survival and correlative analysis","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100067"}}